Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-1101 in Advanced Refractory Solid Tumors
NCT03195764Phase 1Terminated
- Sponsor
- Taivex Therapeutics
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-1101 in solid tumor, sponsored by Taivex Therapeutics. Primary endpoint: Maximum Tolerated Dose. Started Sep 2017; status: terminated.
02
Drugs
T-1101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03195764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195764.